{"product_id":"artificial-intelligence-and-meningioma-how-computers-are-learning-to-help-diagnose-and-predict-brain-tumors","title":"Artificial Intelligence and Meningioma: How Computers Are Learning to Help Diagnose and Predict Brain Tumors","description":"\u003cp\u003eThis scoping review examined 52 published studies on how artificial intelligence (AI) is being used to diagnose and manage meningiomas, the most common type of primary brain tumor. The authors found that AI models can automatically outline tumors on MRI scans with high accuracy, predict tumor grade and molecular markers (such as the Ki-67 index) without surgery, and forecast survival and recurrence risk. However, nearly all of the evidence comes from retrospective, single-center studies with inconsistent imaging protocols, so the authors stress that these tools are not yet ready for routine clinical use and require large, prospective, multi-center validation.\u003c\/p\u003e\n\n\u003ch1\u003eArtificial Intelligence and Meningioma: How Computers Are Learning to Help Diagnose and Predict Brain Tumors\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#what-is\"\u003eWhat Is a Meningioma?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ai-terms\"\u003eKey AI Terms Explained Simply\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Researchers Conducted This Review\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#image-analysis\"\u003eAI in Meningioma Image Analysis\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#pathology\"\u003eAI Predicting Tumor Pathology\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#grading\"\u003ePredicting the WHO Grade Without Surgery\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#biomarkers\"\u003ePredicting Molecular Biomarkers: Ki-67 and PR\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#prognosis\"\u003eAI in Prognostic Prediction\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eMajor Limitations and Gaps\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003ePractical Recommendations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eAI models can outline meningiomas on MRI with high accuracy, but most evidence comes from retrospective, single-center studies with inconsistent imaging protocols.\u003c\/li\u003e\n\u003cli\u003eAI can predict tumor grade and molecular markers like Ki-67 and PR from scans, yet these tools are not validated for routine clinical use.\u003c\/li\u003e\n\u003cli\u003eThe central bottleneck is the lack of large, prospective, multi-center validation showing impact on clinical decision-making.\u003c\/li\u003e\n\u003cli\u003ePatients should ask whether AI tools are used at their center as part of a research protocol or established care.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eMeningiomas are the most common primary intracranial tumor — meaning they start inside the skull rather than spreading from elsewhere in the body. They account for approximately \u003cstrong\u003e39% of all central nervous system tumors\u003c\/strong\u003e, which is roughly 4 in every 10 brain and spinal cord tumors. That makes them a substantial burden for neurosurgeons worldwide.\u003c\/p\u003e\n\n\u003cp\u003eMost meningiomas are benign and classified as \u003cstrong\u003eWHO Grade I\u003c\/strong\u003e (World Health Organization Grade I, the least aggressive category). But this is not true for everyone. Between \u003cstrong\u003e20% and 30%\u003c\/strong\u003e of meningiomas — about 1 in 5 to 1 in 3 — are higher-grade tumors (WHO Grade II or III) that behave aggressively and carry a poorer prognosis.\u003c\/p\u003e\n\n\u003cp\u003eCurrent treatment decisions rest heavily on the WHO classification. Doctors may simply monitor asymptomatic low-grade tumors, while symptomatic or high-grade tumors usually require surgical removal, with radiation therapy considered as an add-on treatment.\u003c\/p\u003e\n\n\u003cp\u003eThe problem is that this system has real limits. Before surgery, standard imaging cannot reliably tell doctors the tumor's grade, its molecular features, or how fast its cells are dividing. Prognosis is also imprecise — two patients with the same tumor grade can have very different outcomes. Personalizing treatment is further complicated because doctors cannot easily predict in advance how firm the tumor is, whether it is stuck to nearby tissue, or how well it will respond to radiation.\u003c\/p\u003e\n\n\u003cp\u003eThis is where artificial intelligence comes in. The authors argue that AI could help fill these gaps by extracting information from routine scans that the human eye cannot detect.\u003c\/p\u003e\n\n\u003ch2 id=\"what-is\"\u003eWhat Is a Meningioma?\u003c\/h2\u003e\n\n\u003cp\u003eA meningioma is a tumor that grows from the meninges — the protective layers of tissue that surround the brain and spinal cord. Because of where they grow, even \"benign\" meningiomas can cause serious symptoms by pressing on brain tissue, nerves, or blood vessels.\u003c\/p\u003e\n\n\u003cp\u003eThe WHO grading system sorts meningiomas into three grades based on how the cells look under a microscope and how aggressively they behave. Grade I tumors are the slowest growing. Grade II (sometimes called atypical) and Grade III (anaplastic, meaning highly abnormal and fast-growing) tumors are more likely to return after treatment.\u003c\/p\u003e\n\n\u003cp\u003eGrade matters enormously. It shapes whether a patient needs surgery right away, how much tissue the surgeon tries to remove, and whether radiation therapy is added afterward.\u003c\/p\u003e\n\n\u003ch2 id=\"ai-terms\"\u003eKey AI Terms Explained Simply\u003c\/h2\u003e\n\n\u003cp\u003eBefore diving into the findings, it helps to understand the vocabulary. The authors define these terms carefully, and they are worth knowing because they appear throughout the research.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eArtificial intelligence (AI)\u003c\/strong\u003e: the broad field of making computers perform tasks that normally require human intelligence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMachine learning (ML)\u003c\/strong\u003e: a subset of AI in which computers learn patterns from data rather than being explicitly programmed.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDeep learning (DL)\u003c\/strong\u003e: a powerful type of machine learning that uses multi-layered neural networks (computer systems loosely inspired by the brain) to learn complex patterns.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRadiomics\u003c\/strong\u003e: the high-throughput extraction of quantitative features — hundreds of measurable numerical characteristics — from medical images, which AI models then analyze.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eImaging biomarkers\u003c\/strong\u003e: measurable features from scans that reveal biological information about a tumor, such as its grade or molecular status.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePutting these together, AI can automatically analyze medical images, precisely outline tumors, and pull out high-dimensional radiomic features. When combined with patient clinical information, these models show promise for non-invasively predicting tumor grade, molecular status, and prognosis — all without a single incision.\u003c\/p\u003e\n\n\u003cp\u003eThe authors also note how their review differs from earlier ones. Previous reviews often focused on narrow topics, such as tumor grading alone or a single treatment modality. This review instead covers the entire meningioma care continuum and, importantly, compares how mature and \"ready for prime time\" AI applications are in different tasks.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Researchers Conducted This Review\u003c\/h2\u003e\n\n\u003cp\u003eThis is a \u003cstrong\u003escoping review\u003c\/strong\u003e, a type of study designed to map out all the available evidence on a topic rather than answer one narrow question. The authors followed the Preferred Reporting Items for Systematic Reviews guideline (a widely used checklist that keeps reviews transparent and rigorous) for their search, screening, and data extraction.\u003c\/p\u003e\n\n\u003cp\u003eThe team searched three major databases: \u003cstrong\u003eWeb of Science Core Collection, Scopus, and PubMed\u003c\/strong\u003e. The search was run on \u003cstrong\u003eNovember 9, 2025\u003c\/strong\u003e. To keep results precise, they used a title-based search strategy, looking for the term \"meningioma\" combined with AI-related terms such as machine learning, artificial intelligence, deep learning, and intelligence.\u003c\/p\u003e\n\n\u003cp\u003eAll references were imported into EndNote reference management software, and duplicates were removed. Studies were then screened against pre-set rules.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eStudies were included if they:\u003c\/strong\u003e\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eWere original research articles\u003c\/li\u003e\n  \u003cli\u003eConcerned meningioma\u003c\/li\u003e\n  \u003cli\u003eFocused on developing or validating AI models (including machine and deep learning) applied at any stage of meningioma imaging analysis, diagnosis, grading, prognosis prediction, or treatment decision-making\u003c\/li\u003e\n  \u003cli\u003eHad full text available\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003e\u003cstrong\u003eStudies were excluded if they:\u003c\/strong\u003e\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eWere not published in English\u003c\/li\u003e\n  \u003cli\u003eWere editorials, case reports, conference abstracts, or book chapters\u003c\/li\u003e\n  \u003cli\u003eDid not involve the application or validation of AI models\u003c\/li\u003e\n  \u003cli\u003eHad inaccessible or substandard data\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eTwo researchers screened the studies independently. They first judged titles and abstracts for relevance, then read the full text of potentially eligible papers. Any disagreements were settled by discussion between the two researchers or by a third researcher acting as arbitrator.\u003c\/p\u003e\n\n\u003cp\u003eIn the end, \u003cstrong\u003e52 articles\u003c\/strong\u003e met all criteria and were included in the review.\u003c\/p\u003e\n\n\u003ch2 id=\"image-analysis\"\u003eAI in Meningioma Image Analysis\u003c\/h2\u003e\n\n\u003cp\u003eAI is fundamentally changing how doctors analyze meningioma images. The core idea is to replace a time-consuming, manual process — one that depends heavily on the subjective experience of each physician — with an automated, quantitative, and intelligent tool.\u003c\/p\u003e\n\n\u003cp\u003eThis covers the entire workflow: finding the tumor, outlining it precisely, measuring its volume, and recognizing and classifying its features.\u003c\/p\u003e\n\n\u003cp\u003eOne striking finding: research in this field only began in \u003cstrong\u003e2018\u003c\/strong\u003e, and the number of publications has increased every year since. This tells us that applying AI to meningioma is a relatively young but rapidly growing area of interest.\u003c\/p\u003e\n\n\u003ch3\u003eWhy segmentation matters\u003c\/h3\u003e\n\n\u003cp\u003e\u003cstrong\u003eSegmentation\u003c\/strong\u003e means drawing the exact boundary of a tumor on an image. Accurate segmentation and volume measurement are pivotal for tracking how fast a meningioma grows, planning surgery or radiation, and monitoring whether treatment is working.\u003c\/p\u003e\n\n\u003cp\u003eTraditional methods rely on manual outlining and simple linear measurements, often using geometric assumptions such as the \u003cstrong\u003eABC\/2 method\u003c\/strong\u003e (a formula that estimates volume from three diameter measurements). These old methods are slow, poorly repeatable, and tend to \u003cstrong\u003eoverestimate\u003c\/strong\u003e volume because meningiomas are often irregularly shaped.\u003c\/p\u003e\n\n\u003cp\u003eAI models, especially deep learning architectures based on \u003cstrong\u003econvolutional neural networks (CNNs)\u003c\/strong\u003e — a type of network especially good at processing images — learn complex features directly from image pixels in an end-to-end process.\u003c\/p\u003e\n\n\u003cp\u003eHow well do they work? Performance is typically measured with the \u003cstrong\u003eDice similarity coefficient (DSC)\u003c\/strong\u003e, a score from 0 to 1 that compares the computer's outline with the correct outline (1.0 means perfect overlap).\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eKang and colleagues ran a multicenter study of \u003cstrong\u003e659 patients\u003c\/strong\u003e and reported a DSC of \u003cstrong\u003e0.893\u003c\/strong\u003e on an external validation set using an nnU-Net model — showing real potential for generalization.\u003c\/li\u003e\n  \u003cli\u003eOther studies reported DSCs ranging from \u003cstrong\u003e0.81 to 0.92\u003c\/strong\u003e on internal patient groups.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese numbers deserve context, however. High Dice scores are promising, but their clinical meaning depends on tumor size and location. Segmenting small tumors (less than 1 cm³) or those at the skull base remains more challenging. Also, the reported \"superior\" performance is mainly measured against manual methods or traditional geometric approximations inside controlled research settings — not against the messy reality of diverse hospitals.\u003c\/p\u003e\n\n\u003cp\u003eThat said, comparative analyses suggest AI-based volumetric methods are more resilient to tumor shape variation than traditional linear techniques. But whether this improved technical accuracy actually improves surgical planning efficiency or long-term patient outcomes still needs prospective evaluation (studies that follow patients forward in time).\u003c\/p\u003e\n\n\u003ch3\u003eDetection and feature recognition\u003c\/h3\u003e\n\n\u003cp\u003eAI has also been explored for automatically detecting meningiomas and specific imaging features, such as the \u003cstrong\u003edural tail sign\u003c\/strong\u003e (a tapering enhancement along the brain lining often seen with meningiomas).\u003c\/p\u003e\n\n\u003cp\u003eProof-of-concept studies report high detection sensitivities and classification accuracies on specific test sets. However, these results often come from relatively small, curated datasets. Two problems are not yet fully characterized: false positives caused by structures that mimic tumors, and how the models perform on truly independent, prospectively collected screening data. The authors conclude this application remains in a developmental phase, not a clinical routine.\u003c\/p\u003e\n\n\u003ch3\u003eCombining segmentation with diagnosis\u003c\/h3\u003e\n\n\u003cp\u003eSome of the most advanced work combines segmentation with diagnostic tasks in a single system. These end-to-end systems both outline the tumor and predict its WHO grade.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eZhang and colleagues reported a grading accuracy of \u003cstrong\u003e81.52%\u003c\/strong\u003e alongside their segmentation performance.\u003c\/li\u003e\n  \u003cli\u003eChen and colleagues achieved an \u003cstrong\u003eAUC of 0.918\u003c\/strong\u003e for grade prediction in their validation group.\u003c\/li\u003e\n  \u003cli\u003eJun and colleagues achieved an \u003cstrong\u003eAUC of 0.770\u003c\/strong\u003e in their validation group.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e(The AUC, or area under the curve, is a score from 0.5 to 1.0, where 0.5 means the model is guessing and 1.0 means perfect discrimination.)\u003c\/p\u003e\n\n\u003cp\u003eNotably, some studies show that radiomic features extracted from AI-generated segmentations are comparable to those from manual outlines. That supports using automation for downstream analysis. Interpretability tools, such as attention mapping — which highlights which parts of an image influenced the model's decision — also help build trust.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe bottom line on image analysis:\u003c\/strong\u003e the technical feasibility is strongly supported. But most evidence comes from retrospective, single-center or limited multi-center studies, with variability in sample sizes, class imbalance (too few high-grade tumors) and inconsistent MRI protocols across institutions.\u003c\/p\u003e\n\n\u003ch2 id=\"pathology\"\u003eAI Predicting Tumor Pathology\u003c\/h2\u003e\n\n\u003cp\u003eAccurate pathological assessment is essential for treatment planning and prognosis. The WHO grading system is the foundation, and it directly shapes treatment strategy. Traditionally, grading has relied solely on examining tissue removed during surgery — an invasive and time-consuming process.\u003c\/p\u003e\n\n\u003cp\u003eAI offers a different path: extracting quantitative features from routine preoperative MRI that the human eye cannot discern, enabling non-invasive, precise prediction of grade before any surgery happens.\u003c\/p\u003e\n\n\u003ch2 id=\"grading\"\u003ePredicting the WHO Grade Without Surgery\u003c\/h2\u003e\n\n\u003cp\u003eDistinguishing low-grade (Grade I) from high-grade (Grade II\/III) tumors before surgery is a major focus of AI research, because this directly affects surgical planning and whether added therapy like radiation is needed.\u003c\/p\u003e\n\n\u003cp\u003eThe earliest efforts used machine learning models built on manually defined radiomic features:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHale and colleagues\u003c\/strong\u003e reported an artificial neural network (ANN) model achieving an \u003cstrong\u003eAUC of 0.89\u003c\/strong\u003e using MRI features interpreted by neuroradiologists.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePark and colleagues\u003c\/strong\u003e showed that combining features from multiparametric MRI — conventional MRI (cMRI), apparent diffusion coefficient (ADC) maps, and susceptibility-weighted imaging (SWI) — could improve performance, highlighting the value of multi-sequence data.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese studies proved the concept, but their reliance on subjective feature definitions and often modest sample sizes limits how well they apply to new patients.\u003c\/p\u003e\n\n\u003cp\u003eWith deep learning, the field shifted toward CNNs, which learn features autonomously from raw images and avoid the subjectivity and information loss of manual feature extraction.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eZhu and colleagues\u003c\/strong\u003e developed a deep learning radiomics (DLR) model using conventional contrast-enhanced T1-weighted MRI. It achieved an \u003cstrong\u003eAUC of 0.811\u003c\/strong\u003e in an independent validation group — significantly outperforming handcrafted-feature radiomics models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBanzato and colleagues\u003c\/strong\u003e compared the Inception-V3 and AlexNet models, pre-trained on ADC maps and enhanced T1-weighted images. Inception-V3, based on ADC maps, achieved the best diagnostic accuracy. Both models performed poorly on enhanced T1-weighted images, showing that model architecture and image sequence choice matter. The \u003cstrong\u003eADC value\u003c\/strong\u003e, which reflects tissue cell density, proved crucial for grading.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJun and colleagues\u003c\/strong\u003e built an interpretable multiparametric deep learning model combining T1-enhanced and T2-weighted images. It achieved fully automatic tumor segmentation (Dice coefficient \u003cstrong\u003e0.910\u003c\/strong\u003e) and tumor grading with an external validation \u003cstrong\u003eAUC of 0.770\u003c\/strong\u003e — surpassing human physicians. Using correlation-weighted class activation mapping (RCAM), they found the model focused mainly on the \u003cstrong\u003esurface region\u003c\/strong\u003e of meningiomas, suggesting it uses features at tumor margins to grade tumors. This insight strengthened clinician trust in the model's reasoning.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSaadh and colleagues\u003c\/strong\u003e conducted a large multicenter study using a fusion strategy that combined handcrafted radiomic features with deep learning features from 3D autoencoders. On T1-enhanced images, this hybrid model achieved state-of-the-art performance. A reproducibility analysis showed that \u003cstrong\u003e127 out of 215 features\u003c\/strong\u003e had high reliability (intraclass correlation coefficient, ICC, greater than 0.75 — meaning repeated measurements agreed closely).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eDespite these encouraging results, serious challenges remain. The key one is \u003cstrong\u003egeneralization\u003c\/strong\u003e: many models perform strongly in internal validation but decline significantly during external multicenter validation. This happens largely because MRI scanning protocols, equipment, and parameters differ across institutions.\u003c\/p\u003e\n\n\u003cp\u003eData imbalance is another frequent problem, especially when high-grade meningiomas are rare in a dataset. Techniques such as the \u003cstrong\u003eSynthetic Minority Oversampling Technique (SMOTE)\u003c\/strong\u003e, which generates synthetic examples of the underrepresented group, serve as effective countermeasures.\u003c\/p\u003e\n\n\u003cp\u003eThe authors make their position clear: AI offers a powerful investigative tool that could inform preoperative planning, but its role in routine clinical decision support is not yet established.\u003c\/p\u003e\n\n\u003ch2 id=\"biomarkers\"\u003ePredicting Molecular Biomarkers: Ki-67 and PR\u003c\/h2\u003e\n\n\u003cp\u003eBeyond grade, certain molecular markers matter for assessing how aggressively a meningioma behaves. Two are especially important.\u003c\/p\u003e\n\n\u003cp\u003eThe \u003cstrong\u003eKi-67 proliferation index\u003c\/strong\u003e measures how many tumor cells are actively dividing. It is considered the gold standard for cell proliferation activity, and its level correlates closely with how fast a meningioma grows and how likely it is to return.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eProgesterone receptor (PR) expression status\u003c\/strong\u003e matters too. Meningiomas often carry progesterone receptors, and negative PR expression typically indicates a more aggressive tumor and lower sensitivity to hormone-based (endocrine) therapy.\u003c\/p\u003e\n\n\u003cp\u003eMultiple studies have tested whether AI can predict these markers from scans:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eA machine learning model using radiomic features from multiparametric MRI, combined with \u003cstrong\u003eLASSO regression\u003c\/strong\u003e (a technique that selects the most useful features) and \u003cstrong\u003esupport vector machine (SVM)\u003c\/strong\u003e algorithms, achieved AUCs of \u003cstrong\u003e0.84 and 0.83\u003c\/strong\u003e in the discovery and independent validation groups. It performed consistently in both skull-base and non-skull-base tumors.\u003c\/li\u003e\n  \u003cli\u003eA \u003cstrong\u003eResNet50\u003c\/strong\u003e model refined through transfer learning achieved an excellent \u003cstrong\u003eAUC of 0.905\u003c\/strong\u003e on the internal test set. Remarkably, it predicted Ki-67, \u003cstrong\u003eH3K27me3\u003c\/strong\u003e (a protein modification linked to tumor behavior), and PR status simultaneously — showing one model can handle multiple predictive tasks.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDuan and colleagues\u003c\/strong\u003e designed a nomogram (a visual scoring tool) integrating clinical features, radiomics scores, and deep transfer learning (DTL) scores. Its predicted AUC of \u003cstrong\u003e0.779\u003c\/strong\u003e for Ki-67 was not statistically significantly different from its sub-models, but it delivered greater net clinical benefit across a broad range of threshold probabilities in decision curve analysis (DCA) — proving useful as a comprehensive assessment tool.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eZhao and colleagues\u003c\/strong\u003e systematically compared clinical imaging features versus radiomic features. They identified \u003cstrong\u003eintratumoral necrosis\u003c\/strong\u003e (dead tissue inside the tumor) and \u003cstrong\u003emaximum tumor diameter\u003c\/strong\u003e as independent predictors of high Ki-67 expression. A clinical-radiomics model incorporating these features achieved an \u003cstrong\u003eAUC of 0.837\u003c\/strong\u003e in internal testing.\u003c\/li\u003e\n  \u003cli\u003eFor PR status, \u003cstrong\u003eGao and colleagues\u003c\/strong\u003e extracted deep transfer learning features from MRI using a finely tuned ResNet50 model. Comparing classifiers — logistic regression (LR), SVM, and Naive Bayes — they found the \u003cstrong\u003eSVM model\u003c\/strong\u003e had the most robust predictive performance, and DCA confirmed its high clinical applicability.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLin and colleagues\u003c\/strong\u003e ran a comprehensive multicenter study extracting radiomic features from T2-weighted and contrast-enhanced T1-weighted images. They integrated these with clinical predictors such as tumor location and enhancement patterns, building a joint model using the \u003cstrong\u003eExtreme Gradient Boosting (XGBoost)\u003c\/strong\u003e algorithm. It performed robustly in the training set and multiple external validation sets, achieving AUC values of \u003cstrong\u003e0.907, 0.827, 0.846, and 0.807\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eTogether, these results point toward detailed molecular subtyping and personalized treatment planning for meningioma patients — all from imaging alone. But the same caveat applies: promising retrospective results do not equal clinical readiness.\u003c\/p\u003e\n\n\u003ch2 id=\"prognosis\"\u003eAI in Prognostic Prediction\u003c\/h2\u003e\n\n\u003cp\u003eBeyond diagnosing and grading, AI models have been developed to forecast what will happen to patients over time. According to the review's findings, AI models have demonstrated robust capabilities in predicting \u003cstrong\u003eoverall survival\u003c\/strong\u003e (how long patients live after diagnosis), \u003cstrong\u003eprogression-free survival\u003c\/strong\u003e (how long patients survive without the tumor growing or returning), and \u003cstrong\u003erecurrence risk\u003c\/strong\u003e (the chance the tumor comes back).\u003c\/p\u003e\n\n\u003cp\u003eThis is a meaningful advance because conventional prognosis is imprecise. Outcomes vary significantly even among patients with the same tumor grade. A tool that could better stratify patients could help doctors decide who needs closer monitoring and who might benefit from more aggressive treatment from the start.\u003c\/p\u003e\n\n\u003cp\u003eThe link between biomarkers and prognosis reinforces why biomarker prediction matters. Because the Ki-67 index is closely tied to tumor growth rate and recurrence risk, an AI model that predicts Ki-67 non-invasively is, indirectly, also supplying prognostic information. The same logic applies to PR status: negative receptor expression signals a more aggressive tumor.\u003c\/p\u003e\n\n\u003cp\u003eThe authors emphasize that this potential must be tested rigorously before it changes practice. Retrospective accuracy is one thing; proving that a model's predictions improve real patient outcomes is another entirely.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eMajor Limitations and Gaps\u003c\/h2\u003e\n\n\u003cp\u003eThe authors are notably candid about the gap between research promise and clinical deployment. Their central criticism applies to nearly every study they reviewed.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRetrospective, single-institution data:\u003c\/strong\u003e Most studies look backward at existing records from one hospital, rather than following patients forward.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSmall datasets:\u003c\/strong\u003e Sample sizes are often modest, raising concerns about overfitting (models memorizing quirks of one dataset rather than learning generalizable patterns).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLack of standardization:\u003c\/strong\u003e Imaging protocols and tumor annotations vary widely, creating risks of data leakage (when information the model should not have access to sneaks in and inflates performance) and poor generalizability.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePerformance drop in external validation:\u003c\/strong\u003e Many models that excel internally decline significantly when tested at other hospitals, largely due to differences in MRI scanners, settings, and protocols.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eClass imbalance:\u003c\/strong\u003e High-grade meningiomas are less common, so training datasets are skewed toward low-grade tumors.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScarcity of prospective trials:\u003c\/strong\u003e There is a near-total absence of prospective, multi-center external validation showing impact on clinical decision-making or patient outcomes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors call this lack of rigorous, prospective, multi-center external validation \u003cstrong\u003e\"the central bottleneck\"\u003c\/strong\u003e hindering reliable clinical integration. Addressing it, they argue, must be the priority for future research.\u003c\/p\u003e\n\n\u003cp\u003eThey also note that even the technical wins need scrutiny. The direct clinical impact of more accurate segmentation — on surgical planning efficiency or long-term outcomes — has not yet been demonstrated.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eIf you or a loved one has been diagnosed with a meningioma, here is what this review suggests about the current state of AI.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAI is not yet part of routine care.\u003c\/strong\u003e Despite impressive research results, no AI tool described here has been validated well enough to replace or reliably supplement standard clinical decision-making. You should be cautious of any clinic marketing AI-based diagnosis as a proven standard.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAI's near-term value is in research and investigation.\u003c\/strong\u003e AI can generate objective, quantitative measurements that support clinical decisions — as an investigative tool, not an established one.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSeveral potential benefits are on the horizon:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eFaster, more consistent tumor volume measurements to track growth over time\u003c\/li\u003e\n  \u003cli\u003eBetter preoperative estimates of tumor grade, which could refine surgical and radiation planning\u003c\/li\u003e\n  \u003cli\u003eNon-invasive estimates of Ki-67 and PR status, potentially reducing the need for some invasive testing\u003c\/li\u003e\n  \u003cli\u003eImproved prognostic information to guide how closely a tumor is monitored\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eInterpretability matters for trust.\u003c\/strong\u003e Some models now reveal which image regions drove their predictions — for example, focusing on the tumor's surface regions when grading. That transparency helps clinicians judge whether a model's reasoning is biologically sensible.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003ePractical Recommendations\u003c\/h2\u003e\n\n\u003cp\u003eBased on this review, here is what the findings suggest for patients, clinicians, and researchers.\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor patients:\u003c\/strong\u003e Ask whether AI tools are used at your center as part of a research protocol or established care. Standard care remains the WHO classification of surgically removed tissue.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor clinicians:\u003c\/strong\u003e Treat AI predictions as supporting information, not definitive answers, until prospective multi-center validation is available.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor researchers:\u003c\/strong\u003e Prioritize large-scale, prospective, multi-center trials with standardized imaging protocols.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor study design:\u003c\/strong\u003e Apply batch effect correction algorithms to handle differences between institutions, and use techniques such as SMOTE to address class imbalance.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor measurement:\u003c\/strong\u003e Demonstrate clinical utility explicitly — not just diagnostic accuracy on retrospective data.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe authors conclude that AI is a formidable new instrument for the precise diagnosis and treatment of meningiomas, with notable potential for clinical translation. Realizing that potential will require closing the gap between promising research and proven real-world benefit.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eCan AI tell me the grade of my meningioma without surgery?\u003c\/h3\u003e\n\u003cp\u003eResearch models can predict whether a meningioma is low-grade or high-grade from MRI scans. For example, one deep learning model using contrast-enhanced T1-weighted MRI achieved an AUC of 0.811 in an independent validation group. However, these tools are not yet ready for routine clinical use and require large, prospective, multi-center validation before they can replace surgical biopsy for grading.\u003c\/p\u003e\n\u003ch3\u003eWhat does an AUC of 0.8 mean for a meningioma AI test?\u003c\/h3\u003e\n\u003cp\u003eAUC stands for area under the curve, a score from 0.5 to 1.0. A value of 0.5 means the model is guessing, while 1.0 means perfect discrimination. So an AUC of 0.8 means the model correctly distinguishes between two groups, such as low-grade and high-grade tumors, about 80% of the time. Higher values indicate better performance.\u003c\/p\u003e\n\u003ch3\u003eCan AI predict if my meningioma will come back?\u003c\/h3\u003e\n\u003cp\u003eAI models have shown potential to forecast recurrence risk, overall survival, and progression-free survival from imaging and clinical data. However, these predictions come from retrospective studies and have not been proven to improve real patient outcomes. They are not yet reliable enough for routine use in guiding monitoring or treatment decisions. More rigorous prospective trials are needed before they can change practice.\u003c\/p\u003e\n\u003ch3\u003eWhat is the Ki-67 index and can AI measure it from my scan?\u003c\/h3\u003e\n\u003cp\u003eThe Ki-67 proliferation index measures how many tumor cells are actively dividing. It is considered the gold standard for cell proliferation activity and correlates with how fast a meningioma grows and how likely it is to return. Several AI models have predicted Ki-67 from MRI scans with AUCs ranging from 0.779 to 0.905 in internal tests, but these are not yet validated for routine clinical use.\u003c\/p\u003e\n\u003ch3\u003eWhy do AI models for meningioma often fail when tested at other hospitals?\u003c\/h3\u003e\n\u003cp\u003eMany models perform well in internal validation but decline significantly during external multicenter validation. This happens largely because MRI scanning protocols, equipment, and parameters differ across institutions. Other issues include small datasets, class imbalance, and lack of standardization. The authors call the lack of rigorous, prospective, multi-center external validation the central bottleneck hindering reliable clinical integration.\u003c\/p\u003e\n\u003ch3\u003eHow accurate is AI at outlining a meningioma on an MRI?\u003c\/h3\u003e\n\u003cp\u003eAI models can automatically outline tumors with high accuracy. In a multicenter study of 659 patients, an nnU-Net model achieved a Dice similarity coefficient of 0.893 on an external validation set. Other studies reported scores from 0.81 to 0.92 on internal patient groups. However, segmenting small tumors or those at the skull base remains more challenging, and clinical benefit is not yet proven.\u003c\/p\u003e\n\u003ch3\u003eI was just diagnosed with a meningioma — when should I get a second opinion on my scans and pathology?\u003c\/h3\u003e\n\u003cp\u003eA meningioma diagnosis rests on the WHO grade of surgically removed tissue, and grade shapes whether surgery is needed, how much tissue is removed, and whether radiation is added. Standard imaging cannot reliably reveal grade, molecular features, or cell division rate before surgery, and prognosis is imprecise even among patients with the same grade. Because treatment decisions depend so heavily on accurate grading, an independent review of your imaging and pathology before committing to a plan is reasonable. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e A scoping review of artificial intelligence applications in meningioma from image analysis to prognostic prediction.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Xu N, Ma W, Dong W, Yin B.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication details:\u003c\/strong\u003e Discover Oncology, 2026; volume 17, article 319. DOI: 10.1007\/s12672-026-04476-5. Published open access under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eStudy type:\u003c\/strong\u003e Scoping review of 52 original research articles identified from Web of Science Core Collection, Scopus, and PubMed as of November 9, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace consultation with a qualified healthcare professional.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47797527412892,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0599\/5449\/5644\/files\/ddn-medical-article-artificial-intelligence-and-meningioma-how-computers-are-learning-to-help-diagnose-and-predict-brain-tumors-hero.png?v=1791868988","url":"https:\/\/diagnosticdetectives.com\/ja\/products\/artificial-intelligence-and-meningioma-how-computers-are-learning-to-help-diagnose-and-predict-brain-tumors","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}